Home Cannabis Cronos Group: Analysts' Recommendations in February

Cronos Group: Analysts’ Recommendations in February

Cronos Group

Cronos Group (CRON) hasn’t reported its earnings yet. Cronos Group has been one of the top choices for investors (HMMJ) along with Canopy Growth (WEED), Tilray (TLRY), and HEXO (HEXO). Jim Cramer called Cronos Group the “second-best” choice. The stock has almost doubled since the beginning of 2019 and closed at 28.6 Canadian dollars on February 19. Let’s look at analysts’ recommendations for the stock over the next 12 months.

Analysts’ recommendation

In February, analysts’ consensus recommendation for Cronos Group was a “buy.” The overall recommendation month-over-month from six analysts remained unchanged. Among the six analysts, one recommended a “strong buy,” while three recommended a “buy” on the stock—one less than in January. wo analysts recommended a “hold” on the stock—up from one analyst a month ago.

Target price

The consensus target price for Cronos Group in February remained unchanged month-over-month at 20 Canadian dollars. The target price is for the next 12-month period. However, Cronos Group stock was trading nearly 1.4x the target price, which indicates that the market is more optimistic than analysts.

Next, we’ll discuss the target price for Aurora Cannabis.

Must Read